Apellis Pharmaceuticals to Present at the 2021 Cantor Virtual Global Healthcare Conference

Apellis Pharmaceuticals (Nasdaq: APLS) announced its participation in the 2021 Cantor Virtual Global Healthcare Conference, scheduled for September 27, 2021, at 8:40 a.m. ET.

Rhea-AI Summary

Apellis Pharmaceuticals (Nasdaq: APLS) announced its participation in the 2021 Cantor Virtual Global Healthcare Conference, scheduled for September 27, 2021, at 8:40 a.m. ET. The conference will be conducted virtually and accessible via a live webcast on the company’s website. A replay will be available for 90 days post-event. Apellis, a leader in targeted C3 therapies, focuses on transformative solutions for diseases caused by complement cascade activation.

Argus Session date unavailable

-3.36% session move Open Argus

Details

News Market Reaction – APLS

The recorded move for APLS in the trading session of this news was -3.36%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will present at the 2021 Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 8:40 a.m. ET. The conference will be held in a virtual meeting format.

The event will be available via live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website at https://investors.apellis.com/events-and-presentations. A replay of the webcast will be available for 90 days following the event.

About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, we aim to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology. For more information, please visit www.apellis.com.

Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Apellis Pharmaceuticals presenting at the 2021 Cantor Virtual Global Healthcare Conference?

Apellis Pharmaceuticals will present at the conference on September 27, 2021, at 8:40 a.m. ET.

How can I access the webcast for the 2021 Cantor Virtual Global Healthcare Conference?

The webcast will be available on the 'Events and Presentations' page of Apellis' website.

Is there a replay available for the Apellis Pharmaceuticals conference presentation?

Yes, a replay of the presentation will be available for 90 days following the event.

What type of therapies does Apellis Pharmaceuticals focus on?

Apellis Pharmaceuticals specializes in targeted C3 therapies for various debilitating diseases.

What are the areas of focus for Apellis Pharmaceuticals' therapies?

Apellis focuses on therapies for conditions in hematology, ophthalmology, nephrology, and neurology.